Jasper Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K reports management changes and related compensation and separation arrangements. The event date is March 17, 2022; the report was signed and furnished on March 21, 2022. Jasper Therapeutics is an emerging growth biotechnology company; this filing does not provide a financial reporting period or operating results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating or financial metrics.
Material Changes
- Jeet Mahal, previously Chief Financial Officer and Chief Business Officer, was promoted to Chief Operating Officer and Chief Financial Officer, effective March 21, 2022.
- Mr. Mahal’s annual base salary increased to $445,000, and his target bonus percentage increased to 45%.
- Kevin N. Heller, M.D., Executive Vice President of Research and Development, entered into a separation agreement on March 17, 2022. His employment is scheduled to terminate on May 17, 2022.
Outlook, Arrangements, Risks and Unusual Items
- Subject to Dr. Heller’s release of claims, the company will retain him as a consultant from May 18, 2022, until the earlier of March 19, 2023, or specified earlier termination events.
- During the consulting period, Dr. Heller will receive approximately $37,939 per month, and the company will pay his COBRA premiums.
- Dr. Heller’s outstanding equity awards will generally continue vesting during the consulting period. If he obtains new employment, awards that would have vested through March 19, 2023, will be deemed fully vested, subject to the agreement’s terms.
- The arrangement creates additional compensation, benefits, and potential equity-vesting costs, but the filing does not quantify the total expense or accounting impact.
- The company stated that Mr. Mahal has no family relationship or reportable related-party transaction involving the appointment.
- The filing references a March 21, 2022 press release furnished as Exhibit 99.1. The separation agreement is expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ending March 31, 2022.
Key Facts for Investor Verification
- Confirm the final terms and conditions of Dr. Heller’s separation and consulting agreement when filed with the Form 10-Q.
- Assess the incremental salary, bonus, consulting, COBRA, and equity-compensation costs in subsequent financial statements.
- Review the March 21, 2022 press release for additional details regarding the management transition.
- Evaluate whether the leadership changes affect research and development execution, clinical programs, or corporate strategy; this filing does not provide that assessment.